Group 1: Business Performance and Strategy - The company's agricultural protection business is nearing the end of its inventory reduction phase, with signs of order volume recovery starting in Q4 2024 [1] - The company will continue to implement a "major customer strategy" while expanding new customer relationships and exploring new product directions [1] - The pharmaceutical business is progressing as planned, with stable development expected and a focus on expanding customer base and enhancing R&D capabilities [2] Group 2: New Energy Business - The company is gradually entering the new energy sector, focusing on products like electrolytes and additives, with a projected revenue breakthrough in 2025 [3] - The competitive landscape in the new energy market is intense, necessitating continuous optimization of technology, quality, and operational efficiency [3] Group 3: International Expansion - The UK subsidiary has undergone cost reduction and production line modifications, achieving partial product sales by Q4 2024 [4] - The Malaysian factory construction is progressing, with plans to start civil engineering in Q1 2025, aiming to meet customer demand with new patented products [4] Group 4: Financial Considerations - The impact of U.S. tariff policy changes on the company's agricultural and pharmaceutical products is limited, as U.S. delivery accounts for a small percentage of total sales [5] - The company plans to invest up to $200 million in the Malaysian base, with phased construction based on order conditions [5]
联化科技(002250) - 2025年3月3日投资者关系活动记录表